FRS2 and ovarian cancer: Firstly, we found that the expression of GLT8D2, FRS2a (Tyr196), AKT (Ser473) and XIAP were significantly increase in six platinum resistant clinical ovarian cancer samples, compared with six platinum sensitive clinical ovarian cancer samples (Fig. 6a).